VPS35: A Potential Drug Target for Neurodevelopmental Disorders

Target Name: VPS35

NCBI ID: G55737

VPS35

VPS35: A Potential Drug Target for Neurodevelopmental Disorders

VPS35, also known as maternal-embryonic 3 (MEND), is a protein that is expressed in the placenta and is known to play a critical role in the development and maintenance of the neural tube, which forms the baby's brain and spinal cord. The neural tube forms during the first week of human development and is crucial for the development of the baby's neural system.

Recent studies have identified VPS35 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The exact mechanism of VPS35's involvement in these diseases is not yet fully understood, but it is known that VPS35 is involved in several important biological processes that are related to disease development.

One of the key functions of VPS35 is its role in the development and maintenance of the neural tube. During the first week of human development, the neural tube forms and is responsible for the early development of the baby's brain and spinal cord. VPS35 is involved in the formation and maintenance of the neural tube by promoting the production of neural tube endoderms, which are the cells that will eventually form the baby's brain and spinal cord.

In addition to its role in the development of the neural tube, VPS35 is also involved in the regulation of the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. VPS35 is known to play a critical role in regulating the cell cycle by promoting the production of new cells in the neural tube.

Another important function of VPS35 is its role in the development and maintenance of the nervous system. VPS35 is involved in the production of the neurotransmitter serotonin, which is important for the functioning of the nervous system. In addition, VPS35 is also involved in the production of other neurotransmitters, including dopamine and GABA.

Recent studies have also identified VPS35 as a potential drug target for various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia. Studies have shown that VPS35 levels are often decreased in individuals with these disorders, and that increasing VPS35 levels may be effective in treating these disorders.

In addition to its potential therapeutic uses, VPS35 is also an important biomarker for the development and progression of various neurological disorders. The neural tube forms during the first week of human development and is a critical template for the development of the baby's brain and spinal cord. Therefore, changes in VPS35 levels may be an important indicator of the early stages of neurodevelopmental disorders.

Overall, VPS35 is a protein that plays a critical role in the development and maintenance of the neural tube, as well as the production of neurotransmitters and the regulation of the cell cycle. Recent studies have identified VPS35 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Further research is needed to fully understand the mechanisms of VPS35's involvement in these diseases and to develop effective treatments.

Protein Name: VPS35 Retromer Complex Component

Functions: Acts as component of the retromer cargo-selective complex (CSC). The CSC is believed to be the core functional component of retromer or respective retromer complex variants acting to prevent missorting of selected transmembrane cargo proteins into the lysosomal degradation pathway. The recruitment of the CSC to the endosomal membrane involves RAB7A and SNX3. The CSC seems to associate with the cytoplasmic domain of cargo proteins predominantly via VPS35; however, these interactions seem to be of low affinity and retromer SNX proteins may also contribute to cargo selectivity thus questioning the classical function of the CSC. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX3-retromer mediates the retrograde endosome-to-TGN transport of WLS distinct from the SNX-BAR retromer pathway (PubMed:30213940). The SNX27-retromer is believed to be involved in endosome-to-plasma membrane trafficking and recycling of a broad spectrum of cargo proteins. The CSC seems to act as recruitment hub for other proteins, such as the WASH complex and TBC1D5 (Probable). Required for retrograde transport of lysosomal enzyme receptor IGF2R and SLC11A2. Required to regulate transcytosis of the polymeric immunoglobulin receptor (pIgR-pIgA) (PubMed:15078903, PubMed:15247922, PubMed:20164305). Required for endosomal localization of WASHC2C (PubMed:22070227, PubMed:28892079). Mediates the association of the CSC with the WASH complex via WASHC2 (PubMed:22070227, PubMed:24980502, PubMed:24819384). Required for the endosomal localization of TBC1D5 (PubMed:20923837)

The "VPS35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets